KLKB1
ENSG00000164344
Target class
Enzyme
Chromosome
4
Approved drugs
5
Clinical candidates (approved and in development)
6
- Approved drugs
- 5
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- KLKB1
- Gene name
- Kallikrein B1
- Gene symbol
- KLKB1
- Previous gene symbols
- KLK3
- Protein name
- Plasma kallikrein (EC 3.4.21.34) (Fletcher factor) (Kininogenin) (Plasma prekallikrein) (PKK) [Cleaved into: Plasma kallikrein heavy chain; Plasma kallikrein light chain]
- Gene biotype
- Protein coding
- Gene family
- Kallikreins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 43
- Highest tissue expression
- 76.49
- Tissue specificity (Gini)
- 0.563
- Tissue specificity (tau)
- 0.965
- KEGG gene identifiers
- hsa:3818
- Protein interaction confidence
- 0.825083
- Protein interaction partners
- 24
- R-HSA-1592389
- R-HSA-9657688
- R-HSA-9657689
- R-HSA-9855719
- R-HSA-9935598
- R-HSA-9970672
- End position
- 186258476
- Start position
- 186225424
- Chromosome
- 4
- Strand
- Forward
- Secreted.
- Tissue specificity (tau)
- 0.964871
- Expression inequality (Gini)
- 0.562545
Expression in transcripts per million
- Liver
- 76.49
- Kidney - Medulla
- 9.26
- Pituitary
- 7.53
- Testis
- 5.3
- Brain - Cerebellar Hemisphere
- 4.96
Expression in transcripts per million
- Liver76.49
- Kidney - Medulla9.26
- Pituitary7.53
- Testis5.3
- Brain - Cerebellar Hemisphere4.96
- Brain - Cerebellum4.68
- Brain - Caudate (basal ganglia)4.66
- Kidney - Cortex4.57
- Brain - Nucleus accumbens (basal ganglia)4.57
- Nerve - Tibial4.43
- Thyroid4.18
- Esophagus - Muscularis3.96
- Spleen3.78
- Esophagus - Gastroesophageal Junction3.64
- Brain - Putamen (basal ganglia)3.63
- Small Intestine - Terminal Ileum3.48
- Colon - Sigmoid3.38
- Brain - Cortex3.34
- Cervix - Endocervix3.33
- Pancreas3.32
- Brain - Anterior cingulate cortex (BA24)3.19
- Fallopian Tube2.98
- Brain - Amygdala2.91
- Artery - Coronary2.83
- Prostate2.82
And 29 more, listed on the interactive page.
- GO:0002542
- GO:0006508
- GO:0031638
- GO:0031639
- GO:0051919
- GO:0005576
- GO:0005886
- GO:0070062
- GO:0004252
- GO:0005515
Related records
Trials (472)
- "The Effect of Inhaled Nitroglycerin for COPD Patients
- 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
- 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
- A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
- A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
- A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
- A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
- A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
- A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
- A Long Term Safety Study of BCX7353 in Hereditary Angioedema
- A Multicenter Clinical Study on Protein Absorption Efficiency in Patients With Pancreatic Exocrine Insufficiency in the ICU
- A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
- A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Efficacy Study
- A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Pharmacokinetic Study
- A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects
- A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
- A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
- A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
Drugs (7)
- Aprotinin Plasma kallikrein inhibitor
- Avoralstat Plasma kallikrein inhibitor
- Berotralstat Plasma kallikrein inhibitor
- Berotralstat hydrochloride Plasma kallikrein inhibitor
- Ecallantide Plasma kallikrein inhibitor
- Human C1-esterase inhibitor Plasma kallikrein inhibitor
- Lanadelumab Plasma kallikrein inhibitor